StemCell Therapy

As we attempt to protect our elderly population in this pandemic, this is what I see when I look through the window,

I look into the window as she awakens to the sound of business outside the door. I can tell that she is not sure who is outside her door. For that matter not sure of the day or time. Is it Wednesday, or Saturday. They all seem the same, day after day unchanging. Someone enters her room with very little conversation. No small talk, places her breakfast box on the tiny table by her chair. I see her say hello and smile at the woman, she just turns to leave. She slowly opens the Styrofoam box to find watery eggs and sausage and a cup of coffee. Her neuropathy wont allow her to open the sugar that she would love to have added to her coffee, but the woman is already gone. She tries to open it but finally puts it down and she just drinks it black. I watch her struggle to eat a few bites of the eggs, dropping them on her shirt. I think she finally figured it is morning. I see she has her TV on, but I know she cant hear much of the show as she is hearing impaired. I notice it has the closed caption on again. I guess she was trying to change the channel. She just cant use that remote and I cant get in to change it myself. She just sits listlessly staring ahead. Loneliness. Is what I see!

I knock on her window to get her attention. She finally looks up. She smiles, it makes me sad to see her happy just to see me through the window, but it is all I can do. Her hair is so disheveled. She would have never looked like this. She always had a standing appointment at the beauty shop weekly for a wash and style. But I guess it doesnt matter, she doesnt ever see her hair. She goes nowhere, only sitting in her room. Alone. I wave at her smiling, while fighting back tears. I hold up my phone to motion that I am going to call her room. I can hear it ringing. I watch her slowly reach for the phone. It continues to ring. Again her neuropathy slows her so much my call is forwarded to voice mail. I call back but now get an instant message. She has not ended the previous call. I finally call the facility and ask someone to please go to her room and help her answer the phone. She smiles as she hears my voice. Why cant these phones be like they used to be? Why cant I just answer it when someone calls me so I can talk to them? Can you please find me a phone like I used to have? Why do I have to push buttons? I cant remember which buttons to push. I just cant use this phone.

Another person with face covered, enters the room, hands her some pills and a sip of water. They are quickly gone. Alone again. She asks if I can just come in for a minute, she has something she wants to tell me. I try to explain that I cant come in at all. I would love to, but I am not allowed. I can only watch from outside the window. She tries to tell me something about last night, but her story is hard to follow. She was never like this, always so lucid with organized thought. This is all changing as I watch from outside the window. She again asks if I can get an appointment to see her. I feel like she thinks she is forgotten; the loneliness is overwhelming. She cannot understand why I dont visit.

I see her plant in the window sill, it needs watering. I tell her the plant needs a drink. But I know she cant water it and the people here are too busy she says. We talk about her breakfast, and I tell her I brought her a few goodies they will deliver to her room. She smiles. I finally tell her that Im leaving as it is cold outside. The smile fades and she says again can you come in for just a minute?

This is what I see from the window! This is one visit at her long term care facility. These visits are increasingly painful to watch and be a part of. The longer she is kept from her family, the worse she gets cognitively and physically. I see the sadness. I see the decline in her health through this window. I know there are others seeing the same as they look through their loved ones windows. The only thing these precious people have done wrong is get old. Now they are forced to live out their last days all alone. I understand we are trying to protect the frail and elderly, but is that really what we are doing?

Teresa Peers

* * *

Amen to Teresa Peers! You are not alone in this fight. I know all the facilities are doing their best to keep people safe, but at what cost?

I think many would choose to take a chance on the virus versus the isolation.

From one caregiver to another, I hear you.

Jeannie Hixon

See the article here:
Our Elderly In Isolation - And Response - The Chattanoogan

A once-per-week selinexor (Xpovio), bortezomib (Velcade), plus dexamethasone treatment strategy appeared effective and convenient as treatment of patients with multiple myeloma who received at least 1 to 3 prior lines of therapy, according to findings from the phase 3, randomized, open-label BOSTON trial.

The study was conducted across 123 sites in 21 countries, and patients were randomized 1:1 to 1 of 2 arms; patients received selinexor 100 mg once per week, bortezomib 1.3 mg/m2 once per week, and dexamethasone 20 mg twice per week, or in the second arm, patients were treated with bortezomib 1.3 mg/m2twice per week for the first 24 weeks and once per week thereafter and dexamethasone 20 mg 4 times per week for the first 24 weeks and twice per week thereafter.

The primary end point of the study is progression-free survival (PFS), and secondary end points included objective response rate (ORR), overall survival (OS), and duration of response (DOR), as well as PFS and ORR in patients who crossed over from the control arm, PFS on subsequent line of therapy, time to next anti-multiple myeloma treatment, time to response, incidence of grade 2 or higher peripheral neuropathy events, and patient-reported peripheral neuropathy. Safety and tolerability were also reviewed as additional secondary end points.

The median age of patients in the experimental arm was 66 years (range, 59-72) compared with 67 years (range, 61-74) in the control arm, and the majority of patients were male in both arms (59% and 56%, respectively). Among patients randomized to the triplet arm (n = 195), 54% had an ECOG performance status of 1, 35% 0, and 10% 2, compared with 55%, 37%, and 8% in the control arm, which included 207 patients total. Most patients (51%) had received 1 prior line of therapy in the experimental arm versus 48% in the control, while 33% and 31% had 2 prior lines, and 16% and 21% had 3 prior lines, respectively.

Overall, the PFS was significantly longer with the triplet regimen compared with bortezomib and dexamethasone alone. The median PFS was 13.93 months (95% CI, 11.73-not evaluable [NE]) in the experimental arm versus 9.46 months (95% CI, 8.11-10.78) in the control arm (HR, 0.70; 95% CI, 0.53-0.93; P=.0075).

The ORR was significantly higher with the once-per-week regimen at 76.4% (95% CI, 69.8-82.2) compared with 62.3% (95% CI, 55.3-68.9) in the control arm (OR, 1.96; 95% CI, 1.3-3.1; P =.0012). In the triplet arm, the proportion of patients with a very good partial response or was 44.6% (95% CI, 37.5-51.9) compared with 32.4% (95% CI, 26.0-39.2) in the bortezomib plus dexamethasone arm (OR, 1.66; 95% CI, 1.1-2.5; P =.0082). The proportion of patients with stable disease or progressive disease as their best response was also lower in the triplet arm at 13.3% (95% CI, 8.9-18.9) compared with 24.2% in the control arm (95% CI, 18.5-30.6).

The median time to first response of a partial response or better was 1.1 months (interquartile range [IQR], 0.8-1.6) in the triplet arm versus 1.4 months (IQR, 0.8-1.6) in the control arm. The median duration of response was longer with the once-per-week regimen at 20.3 months (95% CI, 12.5-NE) compared with 12.9 months (95% CI, 9.3-15.8) in the control (HR, 0.81; 95% CI, 0.56-1.17; P =.1364). The median time to next anti-myeloma therapy was longer in the triplet arm as well at 10.8 months (95% CI, 9.8-13.4) versus 0.66 (95% CI, 0.50-0.86) in the control (P =.0012).

Overall, 47 patients (24%) died in the experimental arm compared with 62 (30%) in the control arm. The median OS was not reached after a median follow-up of 17.3 months in the triplet arm (IQR, 12.9-20.3) versus 25 months (95% CI, 23.5-NE) after 17.5 months follow-up in the experimental arm (HR, 0.84; 95% CI, 0.57-1.23; P =.1852).

In the safety analysis, 195 patients from the triplet arm and 204 from the doublet arm were included. The most common treatment-emergent adverse events (AEs) of grade 3/4 included thrombocytopenia (39% vs 17%), anemia (16% vs 10%, pneumonia (12% vs 10%), and fatigue (13% vs 1%), and these all occurred in higher incidences in the triplet arm compared with the control, respectively.

Treatment was discontinued in 41 (21%) of patients in the experimental arm versus 32 (16%) in the control arm due to treatment-emergent AEs. The most common reasons for treatment discontinuation included peripheral neuropathy (5%), fatigue (4%), nausea (3%), vomiting (2%), decreased appetite (2%), and thrombocytopenia (2%) in the triplet arm, and the most common reason in the control arm was peripheral neuropathy (7%).

The median time to treatment discontinuation was 194 days (IQR, 100-332) in the experimental arm versus 184 (IQR, 106-276) in the control arm, and among all patients who had discontinued, 19 (46%) in the once-per-week arm and 16 (50%) in the bortezomib and dexamethasone arm were over the age of 70 years.

Dose modifications were common in the triplet arm, occurring in 173 (89%) of patients compared with 156 (76%). Most of the side effects that were associated with selinexor were reversible and were mitigated with standard supportive care.

Serious AEs occurred in 101 (52%) of patients in the once-per-week arm versus 77 (38%) in the control arm, and the most frequent serious AE was pneumonia, occurring in 12% of each arm.

Overall, this study demonstrated a significant increase in PFS for patients previously treated with multiple myeloma when treated with the triplet versus the control arm of bortezomib with dexamethasone. The benefit was observed across subgroups, and the improved efficacy was particularly notable in that it was achieved during the first 24 weeks of therapy, according to the study authors.

Reference

Grosicki S, Simonova M, Spicka I, et al.Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.Lancet. 2020;396(10262):P1563-1573. doi: 10.1016/S0140-6736(20)32292-3

More here:
Once-Per-Week Selinexor Triplet Appears Effective in Patients With Multiple Myeloma - Targeted Oncology

Ischemic optic neuropathy is caused due to a small vessel infraction of the optic nerve and is a major cause of blindness or impaired vision among the inflicted. There are two types of ischemic optic neuropathies viz. anterior ischemic optic neuropathy and posterior or non-anterior ischemic optic neuropathy. Anterior ischemic optic neuropathy is caused by the inflammation of arteries supplying blood to the optic nerve whereas posterior or non-anterior ischemic optic neuropathy is caused due to reasons other than inflammation of the arteries. Anterior ischemic optic neuropathy is more prevalent as compared to posterior ischemic optic neuropathy. In anterior ischemic optic neuropathy, immediate treatment is required to prevent vision loss in the fellow eye as approximately 50 percent of cases have chances of blindness in another eye within a span of 5 to 10 days without treatment. The symptoms of ischemic optic neuropathy include unilateral, acute and painless visual loss for hours to days. Hypertension, diabetes, and hypercholesterolemia are some of the well-known risk factors associated with ischemic optic neuropathy disease. Other factors include generalized hypoperfusion, sleep apnea, nocturnal hypotension, vasospasm, severe anemia and failure of autoregulation.

To remain ahead of your competitors, request for a sample [emailprotected]https://www.persistencemarketresearch.com/samples/23077

Technological advancements in ischemic optic neuropathy treatment and availability of alternative drugs are anticipated boost the demand for ischemic optic neuropathy treatments over the forecast period.

The global ischemic optic neuropathy treatment market can be segmented on the basis of disease type, treatment type and end user.

On the basis of disease type, the global ischemic optic neuropathy treatment market can be segmented into:

On the basis of treatment type, the global ischemic optic neuropathy treatment market can be segmented into:

On the basis of end user, the global ischemic optic neuropathy treatment market can be segmented into:

To receive Methodology request here@https://www.persistencemarketresearch.com/methodology/23077

The global ischemic optic neuropathy treatment market is expected to register a significant CAGR over the forecast period. The increasing adoption of recently approved intravitreal implants in the treatment of ophthalmology diseases is anticipated to propel the growth of the ischemic optic neuropathy treatment market over the forecast period. Leading pharmaceutical and drug manufacturing companies from developed countries are substantially investing in R&D, infrastructure and new technologies in ophthalmology therapeutics to capture a market share in the growing burden of eye diseases, which also boosts the growth of the global ischemic optic neuropathy treatment market. With growing awareness towards eye-related complications that lead to blindness, geriatric population and diabetic patients in developed countries, such as the U.S., Russia, and Poland, Germany and Japan are seen to have a proactive approach for treatment related to complications rather than reactive treatment, which also bolsters the growth of the market of ischemic optic neuropathy treatment.

Corticosteroid is the first choice of therapy for patients with ischemic optic neuropathy in prominent countries, such as the U.S., Germany, France, and Russia; however, a majority of patients have developed resistance to anti-VEGF, which leads to the adoption of alternative therapy in patients with ischemic optic neuropathy. This is anticipated to drive the growth of the global ischemic optic neuropathy treatment market in the long run.

To receive extensive list of important regions, Request TOC here @https://www.persistencemarketresearch.com/toc/23077

However, medications such as intravitreal injections of anti-VEGF drugs and corticosteroids lead to an instant increase in intraocular pressure, which may lead to severe adverse effects such as conjunctival haemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased and vitreous detachment. This may restrain the growth of the global ischemic optic neuropathy treatment market.

On the basis of regional presence, the global ischemic optic neuropathy treatment market can segmented into five key regions, namely North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa.

North America is a dominant region in the market and contributes a leading share to the global ischemic optic neuropathy treatment market in terms of revenue. The market in the region is expected to register significant growth over the forecast period due to the availability of developed medical infrastructure and treatment facilities in the region. Europe also contributes a moderate share and registered a healthy growth rate in the global ischemic optic neuropathy treatment market. The APEJ region has become a lucrative market for ischemic optic neuropathy treatment and is anticipated to register a significant share over the forecast period, due to the increase in research and development activities along with the growth in medical tourism in the region. Latin America and MEA are in the nascent stage in the global ischemic optic neuropathy treatment market and are expected to register moderate growth over the forecast period.

Some of the market players operating in the ischemic optic neuropathy treatment market include

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Read more:
The Ischemic Optic Neuropathy Treatment Market to remain unfazed by the Global Recession - Khabar South Asia

A new research study has been presented by dataintelo offering a comprehensive analysis on the Global Lebers Hereditary Optic Neuropathy Drug Market where user can benefit from the complete market research report with all the required useful information about this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The report discusses all major market aspects with expert opinion on current market status along with historic data. This market report is a detailed study on the growth, investment opportunities, market statistics, growing competition analysis, major key players, industry facts, important figures, sales, prices, revenues, gross margins, market shares, business strategies, top regions, demand, and developments.

The Lebers Hereditary Optic Neuropathy Drug Market report provides a detailed analysis of the global market size, regional and country-level market size, segment growth, market share, competitive landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunity analysis, strategic market growth analysis, product launches, and technological innovations.

Get a Free Sample Copy of the Lebers Hereditary Optic Neuropathy Drug Market Report with Latest Industry Trends @ https://dataintelo.com/request-sample/?reportId=127623

Major Players Covered in this Report are: Alkeus Pharmaceuticals, Inc.Biovista Inc.GenSight Biologics S.A.Ixchel Pharma, LLCKhondrion BVSpark Therapeutics, Inc.Stealth BioTherapeutics Inc.

Global Lebers Hereditary Optic Neuropathy Drug Market SegmentationThis market has been divided into Types, Applications, and Regions. The growth of each segment provides an accurate calculation and forecast of sales by Types and Applications, in terms of volume and value for the period between 2020 and 2026. This analysis can help you expand your business by targeting qualified niche markets. Market share data is available on the global and regional level. Regions covered in the report are North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. Research analysts understand the competitive strengths and provide competitive analysis for each competitor separately.

By Types:ElamipretideGS-011IXC-201KH-176Others

By Applications:HospitalClinicOthers

To get Incredible Discounts on this Premium Report, Click Here @ https://dataintelo.com/ask-for-discount/?reportId=127623

Global Lebers Hereditary Optic Neuropathy Drug Market Regions and Countries Level AnalysisRegional analysis is a highly comprehensive part of this report. This segmentation sheds light on the sales of the Lebers Hereditary Optic Neuropathy Drug on regional- and country-level. This data provides a detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market.

The report offers an in-depth assessment of the growth and other aspects of the market in key countries including the US, Canada, Mexico, Germany, France, the UK, Russia, Italy, China, Japan, South Korea, India, Australia, Brazil, and Saudi Arabia. The competitive landscape chapter of the global market report provides key information about market players such as company overview, total revenue (financials), market potential, global presence, Lebers Hereditary Optic Neuropathy Drug sales and revenue generated, market share, prices, production sites and facilities, products offered, and strategies adopted. This study provides Lebers Hereditary Optic Neuropathy Drug sales, revenue, and market share for each player covered in this report for a period between 2016 and 2020.

Make an Inquiry of this Report @ https://dataintelo.com/enquiry-before-buying/?reportId=127623

Why Choose Us:

Table of Contents1. Executive Summary2. Assumptions and Acronyms Used3. Research Methodology4. Market Overview5. Global Market Analysis and Forecast, by Types6. Global Market Analysis and Forecast, by Applications7. Global Market Analysis and Forecast, by Regions8. North America Market Analysis and Forecast9. Latin America Market Analysis and Forecast10. Europe Market Analysis and Forecast11. Asia Pacific Market Analysis and Forecast12. Middle East & Africa Market Analysis and Forecast13. Competition Landscape

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

Read the rest here:
Leber's Hereditary Optic Neuropathy Drug Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 - The Market Feed

New Jersey, United States: Market Research Intellect has added a new report to its huge database of research reports, entitled Neuropathy Pain Treatment Market Size and Forecast to 2027. The report offers a comprehensive assessment of the market including insights, historical data, facts, and industry-validated market data. It also covers the projections using appropriate approximations and methods.

Neuropathy Pain Treatment Market Overview

The Neuropathy Pain Treatment Market Report provides comprehensive data on market dynamics, market trends, product growth rate, and price. The Neuropathy Pain Treatment market report has various facts and statistics assuming the future predictions of the upcoming market participants. In addition, it offers business security taking into account sales, profit, market volume, demand and market supply ratio. The in-depth study provides vital information related to market growth, driving factors, major challenges, opportunities, and threats that will prove to be very helpful for market participants in making upcoming decisions.

Neuropathy Pain Treatment Market: Competitive Landscape

The Neuropathy Pain Treatment Market report consists of the Competitive Landscape section which provides a complete and in-depth analysis of current market trends, changing technologies, and enhancements that are of value to companies competing in the market. The report provides an overview of sales, demand, futuristic costs and data supply as well as a growth analysis in the forecast year. The key vendors in the market that are performing the analysis are also clearly presented in the report. Their development plans, their growth approaches, and their merger and acquisition plans are also identified. Information specific to a keyword in each of these regions is also provided. This report also discusses the submarkets of these regions and their growth prospects.

Prominent players operating in the market:

Neuropathy Pain Treatment Market Segmentation

The report contains the market size with 2019 as the base year and an annual forecast up to 2027 in terms of sales (in million USD). For the forecast period mentioned above, estimates for all segments including type and application have been presented on a regional basis. We implemented a combination of top-down and bottom-up approaches to market size and analyzed key regional markets, dynamics and trends for different applications.

Neuropathy Pain Treatment Market Segment by Type:

Neuropathy Pain Treatment Market Segment by Application:

Neuropathy Pain Treatment Market Regional overview:

In the report, experts analyze and forecast the Neuropathy Pain Treatment market on a global as well as regional level. Taking into account all aspects of the market in terms of regions, the focus of the report is on North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The prevailing trends and various opportunities in these regions are studied that can convince the growth of the market in the forecast period 2020 to 2027.

Reasons to Buy the Neuropathy Pain Treatment Market Report:

Outlook analysis of the Neuropathy Pain Treatment market sector with current trends and SWOT analysis. This study evaluates the dynamics, competition, industrial strategies and strategies of the emerging countries. This report has a comprehensive guide that provides market insights and detailed data on each market segment Market growth factors and risks are presented. More precise information provision on the Neuropathy Pain Treatment market for different countries. Provide visions on factors influencing the growth of the market. Market segmentation analysis, including quantitative and qualitative research considering the impact of economic and non-economic aspects Comprehensive company profiles with product offerings, important financial information and the latest developments.

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

Read the original post:
Neuropathy Pain Treatment Market Size, Share, Statistics, Trends, Demand and Revenue, Forecast To 2027 - The Haitian-Caribbean News Network

Global Ischemic Optic Neuropathy Treatment Market: Overview

Technological progress made in the treatment of ischemic optic neuropathy coupled with the availability of alternative drugs is expected to boost the growth of the global ischemic optic neuropathy treatment market over the period of analysis, from 2020 to 2030. Ischemic optic neuropathies(IONs) are one of the major reasons for seriously impaired vision or blindness usually amongst the elderly and middle-aged people. However, the disease can affect anyone and no human age is immune to it. Increased prevalence of the disease is anticipated to propel expansion of the global ischemic optic neuropathy treatment market in the years to come.

Ischemic optic neuropathies (IONs) come in two types, namely posterior ischemic optic neuropathy (PION) and anterior ischemic optic neuropathy (AION). Inflammation of the arteries that supply blood to the optic nerve causes anterior ischemic optic neuropathy and reasons other than inflammation cause non-anterior ischemic optic neuropathy. However, anterior ischemic optic neuropathy is more commonly found in people than posterior ischemic optic neuropathy. Immediate treatment is needed in case of anterior ischemic optic neuropathy to prevent loss of vision in the affected eye as it also causes damage in the other eye in a span of just 5 to 10 days.

Request Brochure for Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78358

Hypercholesterolemia, diabetes, and hypertension are some of the causes of the disease. In addition, other medical conditions such as failure of autoregulation, severe anemia, vasospasm, nocturnal hypotension, sleep apnea, and hypoperfusion are likely to cause ischemic optic neuropathies.

Disease type, treatment type, end user, and region are the four important parameters based on which the global ischemic optic neuropathy treatment market has been classified. The thorough evaluation of the market comes with the objective of providing stakeholders with a detailed and clear analysis of the global ischemic optic neuropathy treatment market.

Request for Analysis of COVID19 Impact on Ischemic Optic Neuropathy Treatment Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78358

Global Ischemic Optic Neuropathy Treatment Market: Notable Developments

One of the significant developments that give a quick view of the dynamics pertaining to the global ischemic optic neuropathy treatment market is mentioned as below:

Some of the prominent organizations in the global Ischemic optic neuropathy treatment market comprise the below-mentioned:

Pre book Ischemic Optic Neuropathy Treatment Market Report

https://www.transparencymarketresearch.com/checkout.php?rep_id=78358&ltype=S

Global Ischemic Optic Neuropathy Treatment Market: Key Trends

The global ischemic optic neuropathy treatment market is characterized by the presence of the following restraints, drivers, and opportunities.

Increased Demand from Various End Use Sectors to Fuel Market Growth

The development of the global ischemic optic neuropathy treatment market is anticipated to register high growth rate over the tenure of assessment. The increased use of intravitreal implants for treating ophthalmology diseases is expected to open new avenues of growth for the global ischemic optic neuropathy treatment market over the forecast period, from 2020 to 2030. Many of the leading drug manufacturing and pharmaceutical companies from the developed countries are making high investment in the research and development activities so to develop better and advanced solutions and reduce the burden of vision and eye-related diseases. Increased spending in infrastructure and new, advanced technologies in ophthalmology therapeutics are likely to account for a larger share of the market in the years to come.

For patients suffering from ischemic optic neuropathy, corticosteroid is considered as the first choice of therapy, particularly in countries like Russia, France, Germany, and the US. However, several patients have developed resistance to anti-VEGF, which is likely to boost growth of the global ischemic optic neuropathy treatment market over the period of analysis, from 2020 to 2030.

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Read more here:
Ischemic Optic Neuropathy Treatment Market set to witness surge in demand over the forecast period 2020-2030 - Murphy's Hockey Law

Staff Reports Published 6:41 p.m. ChT Nov. 30, 2020

Mark Torre Jr. and his attorney Jay Arriola react after a jury found Torre not guilty of all charges on Nov. 23, 2020. Pacific Daily News

A man sentenced to prison for distributing methamphetamine will be released after the court found substantial evidence of physical ailments, including contracting the coronavirus twice.

On July 25, 2016, the court sentenced Franklin John Salas to nine years imprisonment.Salas has served 60% of his prison sentence, and at sentencing was assigned the lowest criminal history category because his crime was nonviolent.

According to the District Court of Guam, Salas suffers from Type II diabetes, diabetic neuropathy, eye cataracts, hypertension, pressure ulcers on his buttocks and foot, chronic kidney disease, and obesity.

In 2016, he suffered a hip fracture and had surgery. In 2017, he fractured his right knee, which according to court documents, doctors at the prison have been unable to treat.

"Walking on his own is extremely painful, and so (he) has been confined to a wheelchair for the last four years," court documents read. Since the start of his incarceration, Salas gained 50 pounds.

More: GPD investigating skull found on shoreline in Hagta

During the coronavirus outbreak, Salas was infected with the coronavirus twice. He has since suffered chills, body aches, loss of appetite, loss of taste, and fatigue, according to court documents.

"He has difficulty in wheeling himself around because of this fatigue, and thus must always have a fellow prisoner assigned to help push his wheelchair," court documents state. Salas also lives in the same room as dozens of other inmates, and they share three bathrooms and one urinal.

More: Don't click that link: Free chicken announcement on WhatsApp is a hoax, KFC Guam says

The court has reduced his sentence to the time he served, and will release him, subject to the surrender of his passport and regular monitoring.

Salas still faces three years of supervised release, during which he will have to comply with conditions already imposed on him.

Read or Share this story: https://www.guampdn.com/story/news/local/2020/11/30/man-jailed-distributing-methamphetamine-released-after-proof-physical-ailments/6461376002/

Continue reading here:
Man jailed for distributing methamphetamine to be released after proof of physical ailments - Pacific Daily News

MediciNovaannounced today that it received positive Optical Coherence Tomography (OCT) results from its SPRINT-MS Phase IIb trial of MN-166 (ibudilast) in multiple sclerosis (MS) subjects. The results were published in the Multiple Sclerosis Journal.

A total of 28 sites participated in the trial, with 22 sites using Zeiss Cirrus OCT and six sites utilizing Heidelberg Spectralis OCT. In all, 183 subjects were imaged with Cirrus, while 61 were imaged with Spectralis. All of the OCT measures showed less loss of retinal tissue in subjects who received MN-166, compared to a placebo.

Change in peripapillary retinal nerve fiber layer thickness was +0.0424 uM/year for MN166 (ibudilast) versus 0.2630 uM/year for the placebo. Macular volume change was 0.00503 mm3/year for MN-166 compared to 0.03659 mm3/year for placebo in the Spectralis arm. In the Cirrus cohort, macular volume change was 0.00040 mm3/year for MN-166 (ibudilast) compared to 0.02083 mm3/year for the placebo.

We are very pleased that the positive OCT data has been published, said Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, Inc. This data demonstrates that MN-166 can reduce retinal thinning in progressive MS patients and is further evidence of its neuroprotective effect as retinal thinning is associated with brain volume loss and other measures of MS progression.

However, this is not the only condition that MN-166 is being investigated for, according to news published by the company back in September. MediciNova announced earlier this fall that it had received positive clinical findings for MN-166 for the prevention of chemotherapy-induced peripheral neuropathy (CIPN). The results were published in the journal Cancer Chemotherapy and Pharmacology.

Dr. Janette Vardy, Professor of Cancer Medicine, University of Sydney Concord Cancer Centre in Australia, helped lead the research with MediciNova. The authors of the report found that the co-administration of MN-166 with oxaliplatin appeared to result in the improvement or stabilization of oxaliplatin-induced neurotoxicity.

The open-label, sequential crossover study was conducted to determine if MN-166 could reduce acute peripheral neuropathy symptoms in subjects with cancer specifically metastatic upper gastrointestinal or colorectal cancer. A total of 14 patients completed two cycles of oxaliplatin-containing chemotherapy, one cycle with conventional chemotherapy, and one cycle of chemotherapy with concurrent MN-166 treatment.

The subjects underwent a series of assessments for neurotoxicity on Day 3 of each cycle. Once they completed a cycle, they were assessed based on scales including the Oxaliplatin-Specific Neurotoxicity Scale (OSNS), the Total Neuropathy Score Clinical (TNSc), the Functional Assessment of Cancer Therapy/Gynaecologic Oncology GroupNeurotoxicity (FACT/GOG-Ntx13), and the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) neuropathy subscale. Across all neurotoxicity measures, most respondents experienced either an improvement or no worsening of neurotoxicity with MN-166 treatment.

We are very pleased to report positive results from this study, Iwaki said at the time of the results publication. Acute neurotoxicity, which predicts chronic CIPN, usually recurs with oxaliplatin chemotherapy and in most cases, patients experience worsening of neurotoxicity symptoms with continued chemotherapy. What makes this remarkable is that half of participants reported improved symptoms in the acute period and showed improved neurological parameters on clinical assessment with ibudilast treatment.

MN-166 is a first-in-class, orally bioavailable, small molecule macrophage migration inhibitory factor inhibitor. It is also a phosphodiesterase (PDE) -4 and -10 inhibitor that suppresses pro-inflammatory cytokines. MediciNova is developing MN-166 for a wide range of conditions, including progressive MS, ALS and other neurological conditions.

Most read today on BioSpace:

Originally posted here:
MediciNova's Ibudilast Reduces Retinal Thinning in MS Trial Subjects - BioSpace

The global Diabetic Neuropathy Drugs market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Diabetic Neuropathy Drugs market. The research study comes out as a compilation of useful guidelines for players to secure a position of strength in the global Diabetic Neuropathy Drugs market. The authors of the report profile leading companies of the global Diabetic Neuropathy Drugs market, such as Pfizer, Novartis, Johnson & Johnson, Eli Lilly, GlaxoSmithKline, Boehringer Ingelheim, Teva Pharmaceutical, Daiichi Sankyo, Astellas Pharma They provide details about important activities of leading players in the competitive landscape.

The report predicts the size of the global Diabetic Neuropathy Drugs market in terms of value and volume for the forecast period 2019-2026. As per the analysis provided in the report, the global Diabetic Neuropathy Drugs market is expected to rise at a CAGR of XX % between 2019 and 2026 to reach a valuation of US$ XX million/billion by the end of 2026. In 2018, the global Diabetic Neuropathy Drugs market attained a valuation of US$_ million/billion. The market researchers deeply analyze the global Diabetic Neuropathy Drugs industry landscape and the future prospects it is anticipated to create.

This publication includes key segmentations of the global Diabetic Neuropathy Drugs market on the basis of product, application, and geography (country/region). Each segment included in the report is studied in relation to different factors such as consumption, market share, value, growth rate, and production.

Get Sample Copy of This Report:https://www.qyresearch.com/sample-form/form/2301004/global-diabetic-neuropathy-drugs-market

The comparative results provided in the report allow readers to understand the difference between players and how they are competing against each other. The research study gives a detailed view of current and future trends and opportunities of the global Diabetic Neuropathy Drugs market. Market dynamics such as drivers and restraints are explained in the most detailed and easiest manner possible with the use of tables and graphs. Interested parties are expected to find important recommendations to improve their business in the global Diabetic Neuropathy Drugs market.

Readers can understand the overall profitability margin and sales volume of various products studied in the report. The report also provides the forecasted as well as historical annual growth rate and market share of the products offered in the global Diabetic Neuropathy Drugs market. The study on end-use application of products helps to understand the market growth of the products in terms of sales.

Global Diabetic Neuropathy Drugs Market by Product: Calcium Channel Alpha-2 Delta Ligand, SNRIs and TCAs, Others

Global Diabetic Neuropathy Drugs Market by Application: , Hospitals, Drug Stores, Others

The report also focuses on the geographical analysis of the global Diabetic Neuropathy Drugs market, where important regions and countries are studied in great detail.

Global Diabetic Neuropathy Drugs Market by Geography:

Methodology

Our analysts have created the report with the use of advanced primary and secondary research methodologies.

As part of primary research, they have conducted interviews with important industry leaders and focused on market understanding and competitive analysis by reviewing relevant documents, press releases, annual reports, and key products.

For secondary research, they have taken into account the statistical data from agencies, trade associations, and government websites, internet sources, technical writings, and recent trade information.

Enquire For Customization in the Report:https://www.qyresearch.com/customize-request/form/2301004/global-diabetic-neuropathy-drugs-market

Key questions answered in the report:

Get Full Report in your Inbox within 24 Hours at USD(3350): https://www.qyresearch.com/settlement/pre/52a1fd0b8152186a4052820d2a5020fd,0,1,global-diabetic-neuropathy-drugs-market

Table Of Contents:

1 Market Overview of Diabetic Neuropathy Drugs1.1 Diabetic Neuropathy Drugs Market Overview1.1.1 Diabetic Neuropathy Drugs Product Scope1.1.2 Market Status and Outlook1.2 Global Diabetic Neuropathy Drugs Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Diabetic Neuropathy Drugs Market Size by Region (2015-2026)1.4 Global Diabetic Neuropathy Drugs Historic Market Size by Region (2015-2020)1.5 Global Diabetic Neuropathy Drugs Market Size Forecast by Region (2021-2026)1.6 Key Regions, Diabetic Neuropathy Drugs Market Size YoY Growth (2015-2026)1.6.1 North America Diabetic Neuropathy Drugs Market Size YoY Growth (2015-2026)1.6.2 Europe Diabetic Neuropathy Drugs Market Size YoY Growth (2015-2026)1.6.3 Asia-Pacific Diabetic Neuropathy Drugs Market Size YoY Growth (2015-2026)1.6.4 Latin America Diabetic Neuropathy Drugs Market Size YoY Growth (2015-2026)1.6.5 Middle East & Africa Diabetic Neuropathy Drugs Market Size YoY Growth (2015-2026) 2 Diabetic Neuropathy Drugs Market Overview by Type2.1 Global Diabetic Neuropathy Drugs Market Size by Type: 2015 VS 2020 VS 20262.2 Global Diabetic Neuropathy Drugs Historic Market Size by Type (2015-2020)2.3 Global Diabetic Neuropathy Drugs Forecasted Market Size by Type (2021-2026)2.4 Calcium Channel Alpha-2 Delta Ligand2.5 SNRIs and TCAs2.6 Others 3 Diabetic Neuropathy Drugs Market Overview by Application3.1 Global Diabetic Neuropathy Drugs Market Size by Application: 2015 VS 2020 VS 20263.2 Global Diabetic Neuropathy Drugs Historic Market Size by Application (2015-2020)3.3 Global Diabetic Neuropathy Drugs Forecasted Market Size by Application (2021-2026)3.4 Hospitals3.5 Drug Stores3.6 Others 4 Global Diabetic Neuropathy Drugs Competition Analysis by Players4.1 Global Diabetic Neuropathy Drugs Market Size by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Neuropathy Drugs as of 2019)4.3 Date of Key Manufacturers Enter into Diabetic Neuropathy Drugs Market4.4 Global Top Players Diabetic Neuropathy Drugs Headquarters and Area Served4.5 Key Players Diabetic Neuropathy Drugs Product Solution and Service4.6 Competitive Status4.6.1 Diabetic Neuropathy Drugs Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Pfizer5.1.1 Pfizer Profile5.1.2 Pfizer Main Business5.1.3 Pfizer Diabetic Neuropathy Drugs Products, Services and Solutions5.1.4 Pfizer Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.1.5 Pfizer Recent Developments5.2 Novartis5.2.1 Novartis Profile5.2.2 Novartis Main Business5.2.3 Novartis Diabetic Neuropathy Drugs Products, Services and Solutions5.2.4 Novartis Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.2.5 Novartis Recent Developments5.3 Johnson & Johnson5.5.1 Johnson & Johnson Profile5.3.2 Johnson & Johnson Main Business5.3.3 Johnson & Johnson Diabetic Neuropathy Drugs Products, Services and Solutions5.3.4 Johnson & Johnson Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.3.5 Eli Lilly Recent Developments5.4 Eli Lilly5.4.1 Eli Lilly Profile5.4.2 Eli Lilly Main Business5.4.3 Eli Lilly Diabetic Neuropathy Drugs Products, Services and Solutions5.4.4 Eli Lilly Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.4.5 Eli Lilly Recent Developments5.5 GlaxoSmithKline5.5.1 GlaxoSmithKline Profile5.5.2 GlaxoSmithKline Main Business5.5.3 GlaxoSmithKline Diabetic Neuropathy Drugs Products, Services and Solutions5.5.4 GlaxoSmithKline Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.5.5 GlaxoSmithKline Recent Developments5.6 Boehringer Ingelheim5.6.1 Boehringer Ingelheim Profile5.6.2 Boehringer Ingelheim Main Business5.6.3 Boehringer Ingelheim Diabetic Neuropathy Drugs Products, Services and Solutions5.6.4 Boehringer Ingelheim Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.6.5 Boehringer Ingelheim Recent Developments5.7 Teva Pharmaceutical5.7.1 Teva Pharmaceutical Profile5.7.2 Teva Pharmaceutical Main Business5.7.3 Teva Pharmaceutical Diabetic Neuropathy Drugs Products, Services and Solutions5.7.4 Teva Pharmaceutical Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.7.5 Teva Pharmaceutical Recent Developments5.8 Daiichi Sankyo5.8.1 Daiichi Sankyo Profile5.8.2 Daiichi Sankyo Main Business5.8.3 Daiichi Sankyo Diabetic Neuropathy Drugs Products, Services and Solutions5.8.4 Daiichi Sankyo Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.8.5 Daiichi Sankyo Recent Developments5.9 Astellas Pharma5.9.1 Astellas Pharma Profile5.9.2 Astellas Pharma Main Business5.9.3 Astellas Pharma Diabetic Neuropathy Drugs Products, Services and Solutions5.9.4 Astellas Pharma Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.9.5 Astellas Pharma Recent Developments 6 North America6.1 North America Diabetic Neuropathy Drugs Market Size by Country6.2 United States6.3 Canada 7 Europe7.1 Europe Diabetic Neuropathy Drugs Market Size by Country7.2 Germany7.3 France7.4 U.K.7.5 Italy7.6 Russia7.7 Nordic7.8 Rest of Europe 8 Asia-Pacific8.1 Asia-Pacific Diabetic Neuropathy Drugs Market Size by Region8.2 China8.3 Japan8.4 South Korea8.5 Southeast Asia8.6 India8.7 Australia8.8 Rest of Asia-Pacific 9 Latin America9.1 Latin America Diabetic Neuropathy Drugs Market Size by Country9.2 Mexico9.3 Brazil9.4 Rest of Latin America 10 Middle East & Africa10.1 Middle East & Africa Diabetic Neuropathy Drugs Market Size by Country10.2 Turkey10.3 Saudi Arabia10.4 UAE10.5 Rest of Middle East & Africa 11 Diabetic Neuropathy Drugs Market Dynamics11.1 Industry Trends11.2 Market Drivers11.3 Market Challenges11.4 Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Disclaimer13.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read more:
Diabetic Neuropathy Drugs Market Growth, Industry Analysis, Size and Share 2026| Pfizer, Novartis, Johnson & Johnson - The Haitian-Caribbean News...

New Jersey, United States: Market Research Intellect has added a new report to its huge database of research reports, entitled Lebers Hereditary Optic Neuropathy Drug Market Size and Forecast to 2027. The report offers a comprehensive assessment of the market including insights, historical data, facts, and industry-validated market data. It also covers the projections using appropriate approximations and methods.

Lebers Hereditary Optic Neuropathy Drug Market Overview

The Lebers Hereditary Optic Neuropathy Drug Market Report provides comprehensive data on market dynamics, market trends, product growth rate, and price. The Lebers Hereditary Optic Neuropathy Drug market report has various facts and statistics assuming the future predictions of the upcoming market participants. In addition, it offers business security taking into account sales, profit, market volume, demand and market supply ratio. The in-depth study provides vital information related to market growth, driving factors, major challenges, opportunities, and threats that will prove to be very helpful for market participants in making upcoming decisions.

Lebers Hereditary Optic Neuropathy Drug Market: Competitive Landscape

The Lebers Hereditary Optic Neuropathy Drug Market report consists of the Competitive Landscape section which provides a complete and in-depth analysis of current market trends, changing technologies, and enhancements that are of value to companies competing in the market. The report provides an overview of sales, demand, futuristic costs and data supply as well as a growth analysis in the forecast year. The key vendors in the market that are performing the analysis are also clearly presented in the report. Their development plans, their growth approaches, and their merger and acquisition plans are also identified. Information specific to a keyword in each of these regions is also provided. This report also discusses the submarkets of these regions and their growth prospects.

Prominent players operating in the market:

Lebers Hereditary Optic Neuropathy Drug Market Segmentation

The report contains the market size with 2019 as the base year and an annual forecast up to 2027 in terms of sales (in million USD). For the forecast period mentioned above, estimates for all segments including type and application have been presented on a regional basis. We implemented a combination of top-down and bottom-up approaches to market size and analyzed key regional markets, dynamics and trends for different applications.

Lebers Hereditary Optic Neuropathy Drug Market Segment by Type:

Lebers Hereditary Optic Neuropathy Drug Market Segment by Application:

Lebers Hereditary Optic Neuropathy Drug Market Regional overview:

In the report, experts analyze and forecast the Lebers Hereditary Optic Neuropathy Drug market on a global as well as regional level. Taking into account all aspects of the market in terms of regions, the focus of the report is on North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The prevailing trends and various opportunities in these regions are studied that can convince the growth of the market in the forecast period 2020 to 2027.

Reasons to Buy the Lebers Hereditary Optic Neuropathy Drug Market Report:

Outlook analysis of the Lebers Hereditary Optic Neuropathy Drug market sector with current trends and SWOT analysis. This study evaluates the dynamics, competition, industrial strategies and strategies of the emerging countries. This report has a comprehensive guide that provides market insights and detailed data on each market segment Market growth factors and risks are presented. More precise information provision on the Lebers Hereditary Optic Neuropathy Drug market for different countries. Provide visions on factors influencing the growth of the market. Market segmentation analysis, including quantitative and qualitative research considering the impact of economic and non-economic aspects Comprehensive company profiles with product offerings, important financial information and the latest developments.

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

More here:
Leber's Hereditary Optic Neuropathy Drug Market Size, Analysis, Growth, Trends, Outlook And Forecast By 2027 - The Haitian-Caribbean News Network

A neurological horror story lies at the centre of Xavier Alfords chilling, stoic and finally revitalising documentary, part of the BBC Storyville strand. Guillain-Barr syndrome is a rare condition that can strike without warning, where the immune system attacks the nerves, sometimes leaving the victim completely paralysed. A passenger in your own body or a weird wormhole you dream all the time is how one person interviewed sums it up though he subsequently recovers.

But director Alford has to suffer a second horror: knowing his fate. Alfords illness, known as multifocal motor neuropathy, is related to Guillain-Barr syndrome but is progressive over many years, palsying the outer extremities first we first see him struggling to grasp his camera. Being, as one clinician points out, the sort of person who wants to know, Alford resolves to learn as much as possible about what awaits him. In what is obviously a therapeutic quest, he spends the film meeting other people in different phases of this chronic neuropathy.

At one point he confronts the worst-case scenario: a patient called Rob, who loses even the ability to communicate with his left eyelid, and has his life support switched off. His wife, while being told it is just a medical decision for which she bears no responsibility, is effectively asked to agree that it is what he would have wanted.

Though the case studies are interesting, Alfords film becomes truly illuminating as he probes this ethical territory in his own life. What is the level of responsibility he has the right to expect of his wife, Anna, and children and his own obligations to communicate his inner experience to them? The film makes this possible for him, but his other half virtually refusing to appear on camera questions if this is appropriate. Who can say? Whats certain is that this bleak, patient inquest is relevant far beyond one rare syndrome.

Locked In: Breaking the Silence is on BFI Player and BBC iPlayer from 30 November.

Go here to see the original:
Locked In: Breaking the Silence review life-affirming story of a devastating illness - The Guardian

In this report, the global Cardiac Autonomic Neuropathy Treatment market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The Cardiac Autonomic Neuropathy Treatment market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Cardiac Autonomic Neuropathy Treatment market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/14518

The major players profiled in this Cardiac Autonomic Neuropathy Treatment market report include:

key players in Cardiac autonomic neuropathy treatment market are Pfizer Inc., Roche Holding AG, Novartis, Amgen Inc., Privi Pharma Limited, Silverline Chemicals Limited, Anthem Biopharma, Praxis Pharmaceutical.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

The regional analysis includes:

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/14518

The study objectives of Cardiac Autonomic Neuropathy Treatment Market Report are:

To analyze and research the Cardiac Autonomic Neuropathy Treatment market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Cardiac Autonomic Neuropathy Treatment manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Cardiac Autonomic Neuropathy Treatment market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the keyword market.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/14518

Visit link:
Cardiac Autonomic Neuropathy Treatment Market Is Pegged To Reach A Value Of US$ XX Mn/Bn By The End Of 2017 2025 - Aerospace Journal

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Chemotherapy Induced Peripheral Neuropathy Treatment market.

Trusted Business Insights presents an updated and Latest Study on Chemotherapy Induced Peripheral Neuropathy Treatment Market. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Chemotherapy Induced Peripheral Neuropathy Treatment market during the forecast period.It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Global Chemotherapy Induced Peripheral Neuropathy Treatment Market and Forecast 2020-2026

CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.

There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.

By region, the United States has the highest share of income, reaching 47.25 percent in 2019.

Market Analysis and Insights: Global Chemotherapy Induced Peripheral Neuropathy Treatment MarketThe research report studies the Chemotherapy Induced Peripheral Neuropathy Treatment market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.

The global Chemotherapy Induced Peripheral Neuropathy Treatment market size is projected to reach US$ 2276.6 million by 2026, from US$ 1572.6 million in 2020, at a CAGR of 6.4% during 2021-2026.Global Chemotherapy Induced Peripheral Neuropathy Treatment Scope and Segment

The global Chemotherapy Induced Peripheral Neuropathy Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Chemotherapy Induced Peripheral Neuropathy Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by

Application for the period 2015-2026.

by Type, the market is primarily split into

by Application, this report covers the following segments

The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.

The Chemotherapy Induced Peripheral Neuropathy Treatment key players in this market include:

Looking for more? Check out our repository for all available reports on Chemotherapy Induced Peripheral Neuropathy Treatment in related sectors.

Quick Read Table of Contents of this Report @ Global Chemotherapy Induced Peripheral Neuropathy Treatment Market and Forecast 2020-2026

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

More:
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market and Forecast 2020-2026 - KYT24

The Neuropathy Pain Treatment Market Report begins with an overview of the industrial chain structure and provides an overview of the industrial environment, analysis of market size, by-products, regions, application forecasts, and market competition with vendors and companies. Introduction to the situation This report describes the profile, as well as the analysis of market prices and the characteristics of the value chain.

This report provides informed decisions, opportunity understanding, effective business strategy planning, new project planning, peer and constraint analysis, and industry forecast projection. Neuropathy Pain Treatment Market Report Includes Breakdown of Top Players, Dealer Strategies, Dealer Analysis, Marketing Channels, Potential Buyers, and Market Development.

Apply FREE Sample Report (Get Full Insights in PDF) with Tables, Charts, and Graphs:https://www.worldwidemarketreports.com/sample/350599

This study provides a detailed analysis of the market in terms of regulatory framework and development trends, historical data, market size, and future prospects. The report provides a detailed analysis of market segments and sub-segments investigating market trends and demand in key regions of the global Neuropathy Pain Treatment market. Joint ventures also refer to various elements such as mergers, partnerships, and product launches.

Global Neuropathy Pain Treatment Market Segmentation as Follows:

By Top Industry Players:, Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals,

By Type:, Calcium channel alpha 2-delta ligands, Serotonin-norepinephrine reuptake inhibitors, Others,

By Application:, Retail Pharmacies, Hospitals, Others,

This research report provides an analysis of the competitive landscape of the global Neuropathy Pain Treatment market. This includes evaluating current and future trends that players can invest in. It also includes an assessment of the players financial prospects and describes the nature of the competition.

The report now describes the changes in market dynamics and demand patterns associated with COVID-19 infection. This report provides a detailed overview of business areas, growth prospects, and future prospects based on the impact of COVID-19 on the growth of the entire industry. The report also provides an analysis of the current and future market impact of Pandemic and a forecast of COVID-19 anomalies.

Get the Free Analysis with this Report (Covers Updated Covid-19 Impact Analysis on Neuropathy Pain Treatment Industry):https://www.worldwidemarketreports.com/covidimpact/350599

The main questions answered in the report are:

The research report describes the potential development opportunities that exist in the global market. The reports are classified by research methods based on historical information and forecasts. The global market for Neuropathy Pain Treatment is generous and dependent on the size and assets of the incentive measurement period. This report provides an understanding of the evolution of openness and control in market making. The search can generate significant awareness of the final destination of the market.

Production Analysis- Production is analyzed for different regions, types and uses. It also provides price analysis to various market participants.

Sales and Revenue Analysis- Examine both sales and revenue in different regions of the global market. Another important aspect that plays an important role in earnings and prices is also evaluated in different regions of this section.

Supply and consumption- This section analyzes the supply and consumption of the market that continues to sell. This part also shows the gap between supply and consumption. Import and export numbers are also listed here.

Other Analytics- Provides market information, sales analysis, and contact information for top manufacturers, suppliers, and top consumers. This includes SWOT analysis of new projects and suitability analysis of new investments.

This data stream also includes sales prices for different types, applications, and regions. An important regional market is offered. It also includes consumption by type and by applicable star.

Do you have any questions? Contact our industry expert:https://www.worldwidemarketreports.com/quiry/350599

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email:sales@worldwidemarketreports.com

Read more:
Global Neuropathy Pain Treatment Market 2020 Comprehensive Analysis, Future Estimations, Growth Drivers and Forecast to 2027 - re:Jerusalem

This article was originally published here

BMC Endocr Disord. 2020 Oct 27;20(1):161. doi: 10.1186/s12902-020-00641-1.

ABSTRACT

BACKGROUND: Vitamin D deficiency is diagnosed by total serum 25-hydroxyvitamin D (25(OH)D) concentration and is associated with poor health and increased mortality; however, some populations have low 25(OH) D concentrations without manifestations of vitamin D deficiency. The Vitamin D Metabolite Ratio (VMR) has been suggested as a superior indicator of vitamin D status. Therefore, VMR was determined in a population with type 2 diabetes at high risk for vitamin D deficiency and correlated with diabetic complications.

RESEARCH DESIGN AND METHODS: Four hundred sisty patients with type 2 diabetes (T2D) were recruited, all were vitamin D3 supplement naive. Plasma concentration of 25-hydroxyvitamin D3 (25(OH)D3) and its metabolites 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and 24,25-dihydroxyvitamin D3 (24,25(OH)2D3) and its epimer, 3-epi-25-hydroxyvitamin D3 (3-epi-25(OH)D3), were measured by LC-MS/MS analysis. VMR-1 was calculated as a ratio of 24,25(OH)2D3:25(OH)D3; VMR-2 as a ratio of 1,25(OH)2D3:25(OH)D3; VMR-3 was calculated as a ratio of 3-epi-25(OH)D3: 25(OH)D3. RESULTS: An association means that there were significant differences between the ratios found for those with versus those without the various diabetic complications studied. VMR-1 was associated with diabetic retinopathy (p = 0.001) and peripheral artery disease (p = 0.012); VMR-2 associated with hypertension (p < 0.001), dyslipidemia (p < 0.001), diabetic retinopathy (p < 0.001), diabetic neuropathy (p < 0.001), coronary artery disease (p = 0.001) and stroke (p < 0.05). VMR-3 associated with hypertension (p < 0.05), dyslipidemia (p < 0.001) and coronary artery disease (p < 0.05).

CONCLUSIONS: In this cross sectional study, whilst not causal, VMR-2 was shown to be the superior predictor of diabetic and cardiovascular complications though not demonstrative of causality in this cross-sectional study population over VMR-1, VMR-3 and the individual vitamin D concentration measurements; VMR-2 associated with both microvascular and cardiovascular indices and therefore may have utility in predicting the development of diabetic complications.

PMID:33109163 | DOI:10.1186/s12902-020-00641-1

Read more:
Vitamin D3 metabolite ratio as an indicator of vitamin D status and its association with diabetes complications - DocWire News

The latest published an effective statistical data titled as Cardiac Autonomic Neuropathy Treatment Market. It defines about the recent innovations, applications and end users of the market. It covers the different aspects, which are responsible for the growth of the industries. Different domains are considered on the basis of the capital of Cardiac Autonomic Neuropathy Treatment market. The analyst examines different companies on the basis of their productivity to review the current strategies. All leading players across the globe, are profiled with different terms, such as product types, industry outlines, sales and much more.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2817289&source=atm

The study throws light on the recent trends, technologies, methodologies, and tools, which can boost the performance of companies. For further market investment, it gives the depth knowledge of different market segments, which helps to tackle the issues in businesses. It includes effective predictions about the growth factors and restraining factors that can help to enlarge the businesses by finding issues and acquire more outcomes. Leading market players and manufacturers are studied to give a brief idea about competitions. To make well-informed decisions in Cardiac Autonomic Neuropathy Treatment areas, it gives the accurate statistical data.

The analyst also focuses on economic and environmental factors, which impacts on the growth of the businesses. For global analysis, the market is examined by considering the different regions such as North America, Latin America, Japan, China, and India. Leading companies are focusing on spreading their products across the regions. Research and development activities of the various industries are included in the report, to decide the flow of the market.

segment by Type, the product can be split intoSolid OralInjectable

Market segment by Application, split intoHospitalsCardiac CentersAmbulatory Surgical Centers

Based on regional and country-level analysis, the Cardiac Autonomic Neuropathy Treatment market has been segmented as follows:North AmericaUnited StatesCanadaEuropeGermanyFranceU.K.ItalyRussiaNordicRest of EuropeAsia-PacificChinaJapanSouth KoreaSoutheast AsiaIndiaAustraliaRest of Asia-PacificLatin AmericaMexicoBrazilMiddle East & AfricaTurkeySaudi ArabiaUAERest of Middle East & Africa

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2817289&source=atm

Competition Analysis

This report examines the ups and downs of the leading key players, which helps to maintain proper balance in the framework. Different global regions, such as Germany, South Africa, Asia Pacific, Japan, and China are analyzed for the study of productivity along with its scope. Moreover, this report marks the factors, which are responsible to increase the patrons at domestic as well as global level.

In the competitive analysis section of the report, leading as well as prominent players of the global Cardiac Autonomic Neuropathy Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.The key players covered in this studyPfizerRoche HoldingNovartisAmgenPrivi PharmaSilverline ChemicalsAnthem BiopharmaPraxis Pharmaceutical

It gives a detailed description of drivers and opportunities in Cardiac Autonomic Neuropathy Treatment market that helps the consumers and potential customers to get a clear vision and take effective decisions. Different analysis models, such as, Cardiac Autonomic Neuropathy Treatment are used to discover the desired data of the target market. In addition to this, it comprises various strategic planning techniques, which promotes the way to define and develop the framework of the industries.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2817289&licType=S&source=atm

The reports conclusion leads into the overall scope of the global market with respect to feasibility of investments in various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the global Cardiac Autonomic Neuropathy Treatment market in the near future. The report will assist understand the requirements of customers, discover problem areas and possibility to get higher, and help in the basic leadership manner of any organization. It can guarantee the success of your promoting attempt, enables to reveal the clients competition empowering them to be one level ahead and restriction losses.

The content of the study subjects, includes a total of 15 chapters:

Chapter 1 Introduction and Overview

Chapter 2 Industry Cost Structure and Economic Impact

Chapter 3 Rising Trends and New Technologies with Major key players

Chapter 4 Global Cardiac Autonomic Neuropathy Treatment Market Analysis, Trends, Growth Factor

Chapter 5 Cardiac Autonomic Neuropathy Treatment Market Application and Business with Potential Analysis

Chapter 6 Global Cardiac Autonomic Neuropathy Treatment Market Segment, Type, Application

Chapter 7 Global Cardiac Autonomic Neuropathy Treatment Market Analysis (by Application, Type, End User)

Chapter 8 Major Key Vendors Analysis of Cardiac Autonomic Neuropathy Treatment Market

Chapter 9 Development Trend of Analysis

Chapter 10 Conclusion

Contact Us:

marketresearchhub

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

About marketresearchhub

marketresearchhub is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

More:
Cardiac Autonomic Neuropathy Treatment Market: Expansion Strategies Set to Generate Substantial Revenue in the near Future - Eurowire

Latest added Global Chemotherapy Induced Peripheral Neuropathy Treatment Market research study offers detailed product outlook and elaborates market review till 2025. The market Study is segmented by key regions that is accelerating the marketization. The study is a perfect mix of qualitative and quantitative Market data collected and validated majorly through primary data and secondary sources.

This report studies the Global Chemotherapy Induced Peripheral Neuropathy Treatment market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the Global Chemotherapy Induced Peripheral Neuropathy Treatment market by companies, region, type and end-use industry.

Request Sample Report @ https://beathanreports.com/request-for-sample-report/14077

to Avail deep insights of Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, competition landscape is provided i.e. Revenue Analysis (M $US) by Company (2017-2019), Segment Revenue Market Share (%) by Players (2017-2019) and further a qualitative analysis is made towards market concentration rate, product/service differences, new entrants and the technological trends in future.

Competitive Analysis:

The major players are focusing highly on innovation in technologies to improving efficiency level. The industry growth outlook is captured by ensuring ongoing process improvements of players and optimal strategies taken up by companies to fight COVID-19 Situation.

The following players are covered in this report:

Aptinyx Inc

Asahi Kasei Pharma Corp

Regenacy Pharmaceuticals

MAKScientific LLC

Metys Pharmaceuticals AG

Nemus Bioscience Inc

PledPharma

Sova Pharmaceuticals Inc

DermaXon LLC

Kineta Inc

Krenitsky Pharmaceuticals Inc

PeriphaGen

Apexian Pharma

WinSanTor

Solasia Pharma K.K.

Request Discount About This Report @ https://beathanreports.com/discount-request-on-report/14077

Market Segments: The Global Chemotherapy Induced Peripheral Neuropathy Treatment Market has been divided into type, application, and region.

Breakdown Data by Type

Calcium Channel 2-delta Ligands

Antidepressants

Opioids

Others

Chemotherapy Induced Peripheral Neuropathy Treatment Breakdown Data by Application

Platinum Agents

Taxanes

Vinca Alkaloids

Others

Based on regional and country-level analysis, the Chemotherapy Induced Peripheral Neuropathy Treatment market has been segmented as follows:

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Nordic

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia-Pacific

Latin America

Mexico

Brazil

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of Middle East & Africa

On The basis of region, the Chemotherapy Induced Peripheral Neuropathy Treatment is segmented into countries, with production, consumption, revenue (million USD), and market share and growth rate in these regions, from 2014 to 2025 (forecast), see highlights below

Have Any Query ask to our Expert @ https://beathanreports.com/get-expert-help/14077

What we can offer in the Strategic Opportunities

We analysts identify in broad terms why some companies are gaining or losing share within a given market segment. Every company have its own story and changes in market share are knowingly the most important indicator of management effectiveness & corporate strategies; it is important to identify those who are succeeding in the market and those who are failing, and the cause of the market flux. Key Financial Ratios are also considered to get towards root-cause analysis of each companies such as Return on Assets, ROCE, and Return on Equity etc. From this understanding of the forces driving the market, the analyst team prepares its strategic recommendations. Ultimately, its that market wisdom, beyond the market data and forecasts, which is the most valuable component of market research studies and provides our clientele with the greatest competitive edge with top level quality standards.

How insights and forecasts from the reports could benefit you:

More here:
Chemotherapy Induced Peripheral Neuropathy Treatment Market to Increase Exponentially During 2020 2027 - Eurowire

Many patients think of cancer care as chemotherapy or surgery to remove a tumor or mass. But, there is one important treatment that is often overlooked: rehabilitation.

Breast cancer, in particular, can leave many patients with painful symptoms and side effects that rehabilitation could help ease.

Weve noticed that many patients with breast cancer have greatly benefited from the rehabilitation care we can provide, says Sean Smith, M.D., an associate professor of physical medicine and rehabilitation at Michigan Medicine and medical director of the Cancer Rehabilitation Program at the University of Michigan Rogel Cancer Center.

The Cancer Rehabilitation Program offers patients, with any type of cancer, at any point in treatment, comprehensive rehabilitation services and care.

One of our most robust programs for patients with breast cancer is the lymphedema program, which involves hands-on therapy by specialty-trained occupational therapists, Smith says. But, we also see a lot of patients greatly improve from symptoms such as pain in the shoulder and chest, and stiffness from aromatase inhibitors, or medications that stop the production of estrogen in postmenopausal women.

Smith says many patients with breast cancer often dont realize rehabilitation care is available for them, and that its performed by experts specifically trained to help the patient group.

The expertise for rehabilitating cancer patients at Michigan Medicine is matched by few institutions, he says. Patients coming here can be sure that they will receive a thorough, detailed and individualized approach to their care by people who understand the complicated and difficult medical treatment they have received.

Here, Smith highlights five reasons why rehabilitation care is important for patients with breast cancer.

1. Rehabilitation care helps to treat the physical and mental side effects of cancer.

Smith says the most common reason for rehabilitation care in patients with breast cancer is chest or shoulder issues after surgery and radiation. This can include pain, tightness, numbness and more.

We also diagnose and treat problems related to chemotherapy, including neuropathy or cognitive issues, aromatase inhibitors, such as stiffness, pain and trigger finger, and the disease itself, such as back pain and cognitive issues with metastatic disease, he says.

The team helps with both the physical aspects of rehabilitation, such as a patient needing supportive braces or having a tough time reaching overhead due to tightness from radiation therapy, as well as the cognitive side effects of cancer treatment.

We help patients that have neuropathy from chemotherapy and we provide options for treatment including balance therapy, Smith says. We also help treat chemobrain, or what patients often describe as a mental cloudiness or cognitive impairment from chemotherapy.

2. Cancer rehabilitation care is specialized to the patients specific needs.

The Cancer Rehabilitation Program practices what they call impairment-driven cancer rehabilitation.

Thats a complicated way of saying we treat whatever problem a patient describes, Smith says. For example, if a patient wants to be able to throw a ball with her grandchild, we work on that. Our program is always 100% patient-centered and individualized to their needs.

Smith says the cancer rehabilitation team includes physicians, physical and occupational therapists, psychologists and additional experts, to address whichever needs a patient is experiencing.

The physicians are cancer rehabilitation physicians, which means that they sub-specialize in treating neurologic, musculoskeletal and cognitive problems that patients experience due to cancer treatment, he says. Our therapists often receive additional certifications to be able to best treat cancer-related issues, including lymphedema, radiation fibrosis and more.

3. Rehabilitation care benefits patients at any point along their cancer treatment timeline.

Whether a patient is currently going through breast cancer treatment, or is in remission, the cancer rehabilitation team is ready to help.

We treat patients all along the cancer treatment timeline from those newly diagnosed, to those who have been free of disease for decades, to those with metastatic disease, Smith says. Before we meet a patient, we conduct a thorough review of their cancer treatment history so that we are prepared to make a plan after talking with the patient.

4. Patients dont need a referral to see a rehabilitation specialist.

Making an appointment with a cancer rehabilitation specialist at Michigan Medicine can be done a couple of ways.

Often times, patients are referred by one of their oncology providers to see either a physician, therapist or psychologist, Smith says. Of course we also have patients call for an appointment without a referral, which is great, too.

He notes that once a patient sees one member of the team, they are sometimes referred to another provider if it would help in their overall treatment.

A physician might refer a patient for lymphedema therapy, or a therapist may suggest a referral to a psychologist if the patient is struggling with cognitive issues, Smith says.

5. Adding rehabilitation care to cancer treatment can benefit a patients quality of life.

Patients who are treated for cancer often are assumed to be back to normal when their treatment ends, but Michigan Medicine and the U-M Rogel Cancer Center recognize that is not the case, Smith says. Its not uncommon for patients to be dealing with the after effects of cancer treatment long after treatment ends.

The rehabilitation team of experts can help restore a patients quality of life, no matter what type of cancer they are experiencing. Smith says the goal is always to get the patient back to doing what they enjoy, whether that be spending time with their family, returning to work or keeping up with their hobbies.

He adds, Patients with breast cancer, or any form of cancer, don't have to endure these issues, but they often don't know how to get help or the amount of help that is available to them. They can take the first step by contacting our team, or asking their doctor for a referral. We would love to meet with them and develop a plan to help them recover from cancer-related symptoms.

Learn more about the Cancer Rehabilitation Program and schedule an appointment.

The rest is here:
5 Reasons Rehabilitation Care is Important After Breast Cancer - University of Michigan Health System News

This article was originally published here

Brain Dev. 2020 Oct 19:S0387-7604(20)30272-2. doi: 10.1016/j.braindev.2020.09.009. Online ahead of print.

ABSTRACT

BACKGROUND: Infantile-onset multisystem neurologic, endocrine, and pancreatic disease (IMNEPD) is an extremely rare autosomal recessive disorder with variable expressivity, caused by biallelic mutations in the PTRH2 gene. Core features are global developmental delay or isolated speech delay, intellectual disability, sensorineural hearing loss, ataxia, and pancreatic insufficiency (both exocrine and endocrine). Additional features may include postnatal microcephaly, peripheral neuropathy, facial dysmorphism, and cerebellar atrophy. In literature, there are only a few anecdotal case reports and none of the previous cases presented with diabetic ketoacidosis.

METHODS: We are reporting a 12-year old adolescent girl with mild intellectual disability who presented with fever, pain abdomen for 2 days, and fast breathing for one day.

RESULTS: Her random blood sugar was 472 mg/dl and arterial blood gas revealed high anion gap metabolic acidosis. Urine examination showed ketonuria. On further evaluation, she was found to have demyelinating sensorimotor polyneuropathy and sensorineural hearing loss. Neuroimaging and other ancillary investigations were normal. Whole exome sequencing revealed a novel homozygous single base pair duplication in exon 1 of the PTRH2 gene (c.127dupA, p.Ser43LysfsTer11), confirming the diagnosis of IMNEPD.

CONCLUSIONS: Apart from describing a novel single base pair duplication causing protein truncation in the PTRH2 gene for the first time, our case also expanded the clinical spectrum of IMNEPD, as this is the first case with seemingly pure neurodevelopmental phenotype, who later developed diabetes mellitus, without any exocrine pancreatic abnormality. IMNEPD should be considered in children or adolescents with global developmental delay or intellectual disability when they develop diabetes mellitus.

PMID:33092935 | DOI:10.1016/j.braindev.2020.09.009

Read more here:
Diabetes mellitus in an adolescent girl with intellectual disability caused by novel single base pair duplication in the PTRH2 gene: Expanding the...

LA JOLLA, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to initiate a multi-center, placebo-controlled, randomized Phase 2b trial to evaluate MN-166 (ibudilast) in chemotherapy-induced peripheral neuropathy (CIPN).

The clinical trial is a collaborative effort between MediciNova, the University of Sydney, and the Australasian Gastro-Intestinal Trials Group (AGITG). Dr. Janette Vardy, Professor of Cancer Medicine, University of Sydney in Australia, will be the lead principal investigator. The proposed clinical trial will evaluate MN-166 (ibudilast) as a potential treatment to reduce acute neurotoxicity severity and CIPN in patients with metastatic colorectal cancer. AGITG will provide funding for this study and MediciNova will provide study drug and regulatory support.

Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc. commented, We are excited to collaborate with Dr. Vardy on this grant-funded study to further explore the potential of MN-166 as a pharmacotherapy for CIPN. As we recently reported, our first clinical trial in CIPN showed that half of participants reported improved symptoms in the acute period and showed improved neurological parameters on clinical assessment with ibudilast treatment. There is a large unmet medical need for patients with this disorder.

Dr. Janette Vardy, the Principal Investigator for this study, commented, The findings from our initial study were encouraging, and with the support of AGITG and MediciNova, we plan to explore further the potential clinical utility of ibudilast in a larger sample of patients who experience oxaliplatin-induced acute neurotoxicity and chronic CIPN.

About the Chemotherapy-induced Peripheral Neuropathy Trial

This study is a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial to determine whether MN-166 (ibudilast) can decrease acute neurotoxicity symptoms and CIPN, and to determine whether ibudilast treatment results in fewer neurotoxicity-induced dose reductions in patients with metastatic colorectal cancer receiving oxaliplatin up to six months. We plan to enroll a total 100 patients in a 1:1 (ibudilast:placebo) ratio. Treatment (MN-166 (ibudilast) 60 mg/day or matching placebo) will commence two days prior to the first cycle of oxaliplatin chemotherapy and will continue for the duration of the oxaliplatin chemotherapy.

About Chemotherapy-induced Peripheral Neuropathy

Peripheral neuropathy is a set of symptoms caused by damage to the nerves that are outside of the brain and spinal cord. These distant nerves are called peripheral nerves. Some of the chemotherapy and other drugs used to treat cancer can damage peripheral nerves that carry sensations to the hands and feet. This damage results in chemotherapy-induced peripheral neuropathy (CIPN) and is a common side effect of cancer chemotherapy. Most commonly, people complain of pins and needles in their toes and fingers. CIPN may affect cancer outcomes due to reductions in chemotherapy dosing and/or premature treatment discontinuation and have a profound impact on quality of life and survivorship. According to a meta-analysis which included more than 4,000 patients, CIPN prevalence was 68% when measured in the first month after chemotherapy, 60% at 3 months, and 30% at 6 months or more (Seretny et al., 2014). Long-term neurotoxicity is an important issue for the growing number of cancer survivors, with the highest number of affected patients having been treated for breast and/or colon cancer.

About MN-166 (ibudilast)

MN-166 (ibudilast) is a first-in-class, orally bioavailable, small molecule macrophage migration inhibitory factor (MIF) inhibitor and phosphodiesterase (PDE) -4 and -10 inhibitor that suppresses pro-inflammatory cytokines and promotes neurotrophic factors. Our earlier human studies demonstrated significant reductions of serum MIF level after treatment with MN-166 (ibudilast). It also attenuates activated glial cells, which play a major role in certain neurological conditions. MN-166 (ibudilast)'s anti-neuroinflammatory and neuroprotective actions have been demonstrated in preclinical and clinical studies, which provide the rationale for treatment of amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (MS) and other neurological diseases such as glioblastoma (GBM), and substance abuse/addiction. MediciNova is developing MN-166 for ALS, progressive MS and other neurological conditions such as degenerative cervical myelopathy (DCM), glioblastoma, substance abuse/addiction, and chemotherapy-induced peripheral neuropathy, as well as prevention of acute respiratory distress syndrome (ARDS) caused by COVID-19. MediciNova has a portfolio of patents which covers the use of MN-166 (ibudilast) to treat various diseases including ALS, progressive MS, and drug addiction.

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market. MediciNova's current strategy is to focus on BC-PIV SARS-COV-2 vaccine for COVID-19, MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), degenerative cervical myelopathy (DCM), substance dependence (e.g., alcohol use disorder, methamphetamine dependence, opioid dependence) and glioblastoma (GBM), as well as prevention of acute respiratory distress syndrome (ARDS) caused by COVID-19, and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MediciNovas pipeline also includes MN-221 (bedoradrine) and MN-029 (denibulin). For more information on MediciNova, Inc., please visit http://www.medicinova.com.

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of BC-PIV SARS-COV-2 vaccine, MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," considering, planning or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of BC-PIV SARS-COV-2 vaccine, MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2019 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

Read more here:
MediciNova, in Collaboration with the University of Sydney and the Australasian Gastro-Intestinal Trials Group, Announces Plans for a Multi-center,...